更多
通知
医学文献 >>
  • 检索发现
  • 增强检索
知识库 >>
  • 临床诊疗知识库
  • 中医药知识库
评价分析 >>
  • 机构
  • 作者
默认
×
更多
在国内外文献保障系统中检索
高级检索 检索偏好
热搜词：
换一批
  • 二次检索
  • 检索历史
论文 期刊
取消
高级检索

检索历史 清除

首页> ESC heart failure> Rationale and design of a multicentre, randomized, placebo-controlled trial of mirabegron, a Beta3-adrenergic receptor agonist on left ventricular mass and diastolic function in patients with structural heart disease Beta3-left ventricular hypertrophy (Beta3-LVH).

Rationale and design of a multicentre, randomized, placebo-controlled trial of mirabegron, a Beta3-adrenergic receptor agonist on left ventricular mass and diastolic function in patients with structural heart disease Beta3-left ventricular hypertrophy (Beta3-LVH).

导出 LinkOut
翻译 打印 收藏 分享
  • 新浪微博
  • 微信
  • QQ空间
  • 豆瓣
 纠错
广告
第一作者： Anne-Catherine,Pouleur
第一单位： Cardiovascular Department, Cliniques Universitaires Saint-Luc, Université catholique de Louvain, Brussels, Belgium.
作者： Anne-Catherine,Pouleur [1] ; Stefan,Anker [2] ; Dulce,Brito [3] ; Oana,Brosteanu [4] ; Dirk,Hasenclever [5] ; Barbara,Casadei [6] ; Frank,Edelmann [7] ; Gerasimos,Filippatos [8] ; Damien,Gruson [9] ; Ignatios,Ikonomidis [8] ; Renaud,Lhommel [10] ; Masliza,Mahmod [11] ; Stefan,Neubauer [11] ; Alexandre,Persu [1] ; Bernhard L,Gerber [1] ; Stefan,Piechnik [11] ; Burkert,Pieske [12] ; Elisabeth,Pieske-Kraigher [6] ; Fausto,Pinto [13] ; Piotr,Ponikowski [14] ; Michele,Senni [15] ; Jean-Noël,Trochu [16] ; Nancy,Van Overstraeten [1] ; Rolf,Wachter [17] ; Jean-Luc,Balligand [18]
作者单位： Cardiovascular Department, Cliniques Universitaires Saint-Luc, Université catholique de Louvain, Brussels, Belgium. [1] Innovative Clinical Trials, Department of Cardiology and Pneumology, University Medical Center Göttingen (UMG), Göttingen, Germany.;Division of Cardiology and Metabolism-Heart Failure, Cachexia and Sarcopenia, Department of Cardiology, Berlin Brandenburg Center for Regenerative Therapies, Charité University of Medicine, Berlin, Germany. [2] Department of Cardiology, CHLN, CCUL (Cardiovascular Centre), AIDFM, Hospital de Santa Maria, Universidade de Lisboa, Lisbon, Portugal. [3] Clinical Trial Centre Leipzig-ZKS, Faculty of Medicine, Leipzig University, Leipzig, Germany. [4] Institute for Medical Informatics, Statistics & Epidemiology-IMISE, Faculty of Medicine, Leipzig University, Leipzig, Germany. [5] Division of Cardiovascular Medicine, Radcliffe Department of Medicine, University of Oxford, John Radcliffe Hospital, Oxford, UK. [6] Department of Internal Medicine and Cardiology, Charité-Universitätsmedizin Berlin-Campus Virchow Klinikum, Berlin, Germany.;German Center for Cardiovascular Research (DZHK), Partner Site, Berlin, Germany.;Berlin Institute of Health (BIH), Berlin, Germany. [7] National and Kapodistrian University of Athens, School of Medicine and Department of Cardiology, Heart Failure Unit, Athens University Hospital Attikon, Athens, Greece. [8] Clinical Biology Department, Cliniques Universitaires Saint-Luc, Université catholique de Louvain, Brussels, Belgium. [9] Nuclear Medicine Department, Cliniques Universitaires Saint-Luc, Université catholique de Louvain, Brussels, Belgium. [10] Cardiovascular Imaging Core Laboratory, Oxford Centre for Clinical Magnetic Resonance Research (OCMR), Division of Cardiovascular Medicine, Radcliffe Department of Medicine, University of Oxford, Oxford, UK. [11] Department of Internal Medicine and Cardiology, Charité-Universitätsmedizin Berlin-Campus Virchow Klinikum, Berlin, Germany.;German Center for Cardiovascular Research (DZHK), Partner Site, Berlin, Germany.;Berlin Institute of Health (BIH), Berlin, Germany.;Department of Internal Medicine and Cardiology, German Heart Institute, Berlin, Germany. [12] Division of Cardiology and Metabolism-Heart Failure, Cachexia and Sarcopenia, Department of Cardiology, Berlin Brandenburg Center for Regenerative Therapies, Charité University of Medicine, Berlin, Germany. [13] Department of Heart Diseases, Wrocław Medical University, Wrocław, Poland.;Cardiology Department, Military Hospital, Wrocław, Poland. [14] Department Cardiovascular Medicine, Cardiology Division, Papa Giovanni XXIII Hospital, Bergamo, Italy. [15] Institut du thorax, Centre Hospitalier Universitaire de Nantes, Nantes, France.;Medical School, University of Nantes, Nantes, France. [16] Clinic for Cardiology and Pneumology, University of Göttingen Medical Centre, Göttingen, Germany.;DZHK (German Centre for Cardiovascular Research), Partner Site Göttingen, Göttingen, Germany. [17] Department of Medicine, Pole of Pharmacology and Therapeutics (FATH), Institut de Recherche Expérimentale et Clinique (IREC), Cliniques Universitaires Saint-Luc, Université catholique de Louvain, B1.53.09, 52 avenue Mounier, 1200, Brussels, Belgium. [18]
关键词 Heart failure with preserved ejection fractionHypertensive structural heart diseaseMirabegronβ3 adrenergic receptor
医学主题词 乙酰苯胺类(Acetanilides);青少年(Adolescent);肾上腺素能β-3受体激动剂(Adrenergic beta-3 Receptor Agonists);成年人(Adult);老年人(Aged);老年人, 80以上(Aged, 80 and over);心舒期(Diastole);疾病恶化(Disease Progression);双盲法(Double-Blind Method);超声心动描记术(Echocardiography);女(雌)性(Female);随访研究(Follow-Up Studies);心室(Heart Ventricles);人类(Humans);肥大, 左心室(Hypertrophy, Left Ventricular);磁共振成像, 电影(Magnetic Resonance Imaging, Cine);男(雄)性(Male);中年人(Middle Aged);前瞻性研究(Prospective Studies);每搏输出量(Stroke Volume);噻唑类(Thiazoles);治疗结果(Treatment Outcome);心室功能, 左(Ventricular Function, Left);心室重构(Ventricular Remodeling);青年人(Young Adult);多中心研究(主题)(Multicenter Studies as Topic);随机对照试验(主题)(Randomized Controlled Trials as Topic)
DOI 10.1002/ehf2.12306
PMID 29932311
发布时间 2026-01-05
基金项目
RG/16/12/32451/BHF_/British Heart Foundation/United Kingdom RG/11/15/29375/BHF_/British Heart Foundation/United Kingdom RE/08/004/BHF_/British Heart Foundation/United Kingdom
提交
  • 浏览8
ESC heart failure

ESC heart failure

2018年5卷5期

830-841页

相似文献

  • 中文期刊
  • 外文期刊
  • 学位论文
  • 会议论文

加载中！

加载中！

加载中！

加载中！

  • 浏览8
ESC heart failure 点击下载 本期目录封面

ESC heart failure

2018年5卷5期

830-841页

相关期刊

加载中！

法律状态公告日 法律状态 法律状态信息

特别提示：本网站仅提供医学学术资源服务，不销售任何药品和器械，有关药品和器械的销售信息，请查阅其他网站。

  • 客服热线：4000-115-888 转3 (周一至周五：8:00至17:00)

  • |

  • 客服邮箱：yiyao@wanfangdata.com.cn

  • 违法和不良信息举报电话：4000-115-888，举报邮箱：problem@wanfangdata.com.cn，举报专区

官方微信
万方医学小程序
new医文AI 翻译 充值 订阅 收藏 移动端

官方微信

万方医学小程序

使用
帮助
Alternate Text
调查问卷